160 related articles for article (PubMed ID: 29409930)
1. The importance of EGFR as a biomarker in molecular apocrine breast cancer.
Liu X; Feng C; Liu J; Liu J; Li C; Xu C; Niu Y
Hum Pathol; 2018 Jul; 77():1-10. PubMed ID: 29409930
[TBL] [Abstract][Full Text] [Related]
2. Heat shock protein 27 and gross cystic disease fluid protein 15 play critical roles in molecular apocrine breast cancer.
Liu X; Feng C; Liu J; Zhao L; Liu J; Zhang W; Liu N; Niu Y
Tumour Biol; 2016 Jun; 37(6):8027-36. PubMed ID: 26711786
[TBL] [Abstract][Full Text] [Related]
3. Subtype classification for prediction of prognosis of breast cancer from a biomarker panel: correlations and indications.
Chen C; Yuan JP; Wei W; Tu Y; Yao F; Yang XQ; Sun JZ; Sun SR; Li Y
Int J Nanomedicine; 2014; 9():1039-48. PubMed ID: 24591826
[TBL] [Abstract][Full Text] [Related]
4. Early versus late distant metastasis and adjuvant chemotherapy alone versus both radiotherapy and chemotherapy in molecular apocrine breast cancer.
Liu X; Yang Y; Feng X; Shen H; Liu J; Liu X; Niu Y
Oncotarget; 2016 Aug; 7(31):48905-48917. PubMed ID: 27340922
[TBL] [Abstract][Full Text] [Related]
5. Apocrine carcinoma as triple-negative breast cancer: novel definition of apocrine-type carcinoma as estrogen/progesterone receptor-negative and androgen receptor-positive invasive ductal carcinoma.
Tsutsumi Y
Jpn J Clin Oncol; 2012 May; 42(5):375-86. PubMed ID: 22450930
[TBL] [Abstract][Full Text] [Related]
6. High snail expression predicts a poor prognosis in breast invasive ductal carcinoma patients with HER2/EGFR-positive subtypes.
Chang HY; Tseng YK; Chen YC; Shu CW; Lin MI; Liou HH; Fu TY; Lin YC; Ger LP; Yeh MH; Liu PF
Surg Oncol; 2018 Jun; 27(2):314-320. PubMed ID: 29937187
[TBL] [Abstract][Full Text] [Related]
7. HER2 status in molecular apocrine breast cancer: associations with clinical, pathological, and molecular features.
Guo W; Wang W; Zhu Y; Zhu X; Shi Z; Wang Y
Int J Clin Exp Pathol; 2015; 8(7):8008-17. PubMed ID: 26339367
[TBL] [Abstract][Full Text] [Related]
8. Potential prognostic tumor biomarkers in triple-negative breast carcinoma.
Peng Y
Beijing Da Xue Xue Bao Yi Xue Ban; 2012 Oct; 44(5):666-72. PubMed ID: 23073572
[TBL] [Abstract][Full Text] [Related]
9. Androgen receptor expression shows distinctive significance in ER positive and negative breast cancers.
Tsang JY; Ni YB; Chan SK; Shao MM; Law BK; Tan PH; Tse GM
Ann Surg Oncol; 2014 Jul; 21(7):2218-28. PubMed ID: 24639191
[TBL] [Abstract][Full Text] [Related]
10. Prognostic significance of geminin expression levels in Ki67-high subset of estrogen receptor-positive and HER2-negative breast cancers.
Yagi T; Inoue N; Yanai A; Murase K; Imamura M; Miyagawa Y; Enomoto Y; Nishimukai A; Takatsuka Y; Hirota S; Akazawa K; Miyoshi Y
Breast Cancer; 2016 Mar; 23(2):224-30. PubMed ID: 25082658
[TBL] [Abstract][Full Text] [Related]
11. HER3 status by immunohistochemistry is correlated with poor prognosis in hormone receptor-negative breast cancer patients.
Bae SY; La Choi Y; Kim S; Kim M; Kim J; Jung SP; Choi MY; Lee SK; Kil WH; Lee JE; Nam SJ
Breast Cancer Res Treat; 2013 Jun; 139(3):741-50. PubMed ID: 23722313
[TBL] [Abstract][Full Text] [Related]
12. Breast Cancer Survival Analysis Based on Immunohistochemistry Subtypes (ER/PR/HER2): a Retrospective Cohort Study.
Poorolajal J; Nafissi N; Akbari ME; Mahjub H; Esmailnasab N; Babaee E
Arch Iran Med; 2016 Oct; 19(10):680-686. PubMed ID: 27743431
[TBL] [Abstract][Full Text] [Related]
13. Triple-negative breast cancer: current state of the art.
Rastelli F; Biancanelli S; Falzetta A; Martignetti A; Casi C; Bascioni R; Giustini L; Crispino S
Tumori; 2010; 96(6):875-88. PubMed ID: 21388048
[TBL] [Abstract][Full Text] [Related]
14. Overexpression of androgen receptor and forkhead-box A1 protein in apocrine breast carcinoma.
Sasahara M; Matsui A; Ichimura Y; Hirakata Y; Murata Y; Marui E
Anticancer Res; 2014 Mar; 34(3):1261-7. PubMed ID: 24596370
[TBL] [Abstract][Full Text] [Related]
15. Distribution and characteristics of androgen receptor (AR) in breast cancer among women in Addis Ababa, Ethiopia: A cross sectional study.
Hadgu E; Seifu D; Tigneh W; Bokretsion Y; Bekele A; Abebe M; Sollie T; Karlsson C; Karlsson MG
PLoS One; 2020; 15(5):e0232519. PubMed ID: 32374753
[TBL] [Abstract][Full Text] [Related]
16. Differences in subtype distribution between screen-detected and symptomatic invasive breast cancer and their impact on survival.
Kobayashi N; Hikichi M; Ushimado K; Sugioka A; Kiriyama Y; Kuroda M; Utsumi T
Clin Transl Oncol; 2017 Oct; 19(10):1232-1240. PubMed ID: 28409323
[TBL] [Abstract][Full Text] [Related]
17. Estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 expression in breast cancer FNA cell blocks and paired histologic specimens: A large retrospective study.
Vohra P; Buelow B; Chen YY; Serrano M; Vohra MS; Berry A; Ljung BM
Cancer Cytopathol; 2016 Nov; 124(11):828-835. PubMed ID: 27315045
[TBL] [Abstract][Full Text] [Related]
18. Correlation between p53 and epidermal growth factor receptor expression in breast cancer classification.
Wang XZ; Liu Q; Sun JJ; Zuo WS; Hu DW; Ma SG; Mu DB; Yu ZY
Genet Mol Res; 2015 Apr; 14(2):4282-90. PubMed ID: 25966200
[TBL] [Abstract][Full Text] [Related]
19. Prognostic Significance of Progesterone Receptor Expression in Estrogen-Receptor Positive, HER2-Negative, Node-Negative Invasive Breast Cancer With a Low Ki-67 Labeling Index.
Ono M; Tsuda H; Yoshida M; Shimizu C; Kinoshita T; Tamura K
Clin Breast Cancer; 2017 Feb; 17(1):41-47. PubMed ID: 27477822
[TBL] [Abstract][Full Text] [Related]
20. Quadruple negative breast cancer.
Huang M; Wu J; Ling R; Li N
Breast Cancer; 2020 Jul; 27(4):527-533. PubMed ID: 31939077
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]